Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + fruquintinib + S-1 + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of sintilimab (an anti-PD-1 antibody), fruquintinib (a highly selective VEGFR 1/2/3 inhibitor), S-1 (an oral fluoropyrimidine), and nab-paclitaxel (an albumin-bound formulation of paclitaxel). This specific four-drug combination appears to be an investigational regimen, though the individual components and some combinations have established clinical profiles.
- Other names
- sintilimab + fruquinitinib + S-1 + nab-paclitaxelSintilimab + Fruquintinib + S-1 plus nab-paclitaxel
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on sintilimab + fruquintinib + S-1 + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + fruquintinib + S-1 + nab-paclitaxel.